Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Ortopedi ve Travmatoloji Kliniği, 06200 Yenimahalle, Ankara, Türkiye.
Jt Dis Relat Surg. 2023 Apr 27;34(2):425-431. doi: 10.52312/jdrs.2023.1048.
The aim of this study was to evaluate the prognostic value of neutrophil-to-lymphocyte ratio (NLR), lymphocyte-tomonocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) in aneurysmal bone cysts (ABCs).
Between February 2001 and August 2019, a total of 86 patients (44 males, 42 females; mean age: 21.5±15.2 years; range, 2 to 73 years) with a histologically confirmed diagnosis of ABCs who did not receive cancer treatment previously and had a minimum follow-up period of 24 months were retrospectively analyzed. Data including age, sex, side, tumor location, pre-treatment complete blood count analysis results, preferred surgical method, follow-up period, presence of recurrence, and date of recurrence were recorded. Preoperative NLR, LMR and PLR values were calculated in all patients.
The mean follow-up was 56.7±13.5 (range, 24 to 179) months. Forty-one (47.7%) ABCs were located in the lower extremities, 36 (41.8%) in the upper extremities, and nine (10.4%) in the pelvic girdle. A statistically significant difference was detected in the NLR values according to recurrence status (p=0.023). The PLR and LMR values were not significant for area under the curve, while NLR values were significant for recurrence. The cut-off value was determined as 2.054. Those with an NLR of ≥2.054 were found to have a 4.561-fold higher risk of recurrence than those with an NLR of <2.054 (odds ratio [OR]=4.561).
Our study results suggest that NLR, which is the pre-treatment inflammatory index, is a prognostic factor in patients with ABCs. Although NLR alone is not decisive in patients with elevated NLR, it can be used to evaluate the clinical prognosis and recommend an appropriate treatment strategy.
本研究旨在评估中性粒细胞与淋巴细胞比值（NLR）、淋巴细胞与单核细胞比值（LMR）和血小板与淋巴细胞比值（PLR）在骨巨细胞瘤（ABC）中的预后价值。
回顾性分析了 2001 年 2 月至 2019 年 8 月期间，86 例经组织学证实为 ABC、既往未接受癌症治疗且随访时间至少 24 个月的患者的临床资料。记录患者的年龄、性别、侧别、肿瘤部位、治疗前全血细胞计数分析结果、首选手术方法、随访时间、是否复发以及复发时间等数据。所有患者均计算术前 NLR、LMR 和 PLR 值。
平均随访时间为 56.7±13.5（范围，24-179）个月。41 例（47.7%）ABC 位于下肢，36 例（41.8%）位于上肢，9 例（10.4%）位于骨盆带。根据复发情况，NLR 值存在统计学差异（p=0.023）。PLR 和 LMR 值的曲线下面积无统计学意义，而 NLR 值对复发有意义。确定的截断值为 2.054。NLR≥2.054 的患者复发风险是 NLR<2.054 的患者的 4.561 倍（比值比[OR]=4.561）。
本研究结果表明，NLR 作为治疗前炎症指标，是 ABC 患者的预后因素。虽然 NLR 本身并不能决定 NLR 升高的患者，但可以用于评估临床预后并推荐合适的治疗策略。
